ProPhase Labs에 대한 매도 수량은 투자자에게 ProPhase Labs의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

ProPhase Labs (NASDAQ:PRPH) 주식, 공매도 수량 보고

ProPhase Labs

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Asset Sales

BLCO

FYBR

PRPH

WOLF

뉴 온 더 블록 아리 엠마누엘(Ari Emanuel)의 스포츠 및 엔터테인먼트 대기업인 엔데버 그룹 홀딩스(NYSE:EDR)는 마이애미 오픈 및 마드리드 오픈 테니스 토너먼트를 포함한 IMG 테니스 자산 매각 가능성을 검토하고 있다. IMG의 다른 자산 대부분은 UFC(얼티밋 파이팅 챔피언십) 및 WWE(월드 레슬링 엔터테인먼트)의 모회사인 TKO 그룹 홀딩스(NYSE:TKO)와의 목요일에 발표된 거래에 포함되었다.

딜 디스패치: UFC, WWE 모회사 TKO가 불 라이딩 인수; 엔데버가 테니스 자산 매각 검토 등

ProPhase Labs Inc

Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights
GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) (the "Company" or "ProPhase"), a next generation biotech, genomics, and diagnostics company, today announced the launch of DNA Complete, Inc., a wholly owned subsidiary, offering a groundbreaking direct-to-consumer DNA test that sequences virtually 100% of a customer's genome. This new service provides customers with in-depth insights into health, wellness, and ancestry.
DNA Complete – A New Paradigm in Direct-to-Consumer DNA Testing
<ul>
<li>Comprehensive Whole Genome Sequencing: Unlike traditional DNA Ancestry tests that analyze small snippets of DNA, DNA Complete offers a full genomic view, empowering customers with detailed health and wellness information alongside enhanced ancestry data.</li>
<li>Strategic Leadership Addition: ProPhase retained Stu Hollenshead, former Chief Business Officer and COO of Barstool Sports and current CEO of 10PMCurfew, to spearhead marketing efforts.</li>
<li>Influencer-Driven Marketing Campaign: A robust marketing initiative featuring top social media influencers is set to launch and aims to maximize reach and engagement.</li>
<li>Competitive Pricing and Robust Platform: DNA Complete is designed to offer a robust genetic user platform at competitive pricing which makes advanced genomic insights accessible to a wider audience.</li>
<li>Cutting-Edge Bioinformatics and Ancestry Analysis: The service leverages its advanced bioinformatics platform and introduces a proprietary, sophisticated ancestry platform.</li>
<li>Flexibility with Sample Processing: DNA Complete provides the flexibility to send samples to ProPhase Labs' other wholly owned subsidiary, Nebula Genomics, as well as other leading genetics labs, ensuring the highest quality results and efficient pricing and turnaround times.</li>
<li>Continuous Engagement Through Subscription: The DNA Complete subscription service ensures ongoing customer engagement by providing regular updates and new insights. The subscription model is a high margin business that we expect will create longer term cash flow.</li>
<li>Genetic Counseling Services: To enhance the value proposition, DNA Complete offers genetic counseling to help customers interpret their data effectively.</li>
</ul>
DNA Expand – Enhancing Existing DNA Ancestry Data
<ul>
<li>Effortless Data Upload: Consumers can easily upload their DNA data from other ancestry tests to unlock ProPhase's proprietary health and wellness reports.</li>
<li>Significant Data Expansion: Users' existing DNA files are amplified with 50 times more data than available through traditional DNA ancestry tests, delivering more in-depth insights without the need for additional sequencing.</li>
<li>Flexible Subscription Options: Monthly and yearly subscriptions are available, with new reports added regularly to keep customers informed.</li>
<li>Significant Target Market: A recent estimate indicates that more than 26 million people worldwide have undergone genetic ancestry testing by direct-to-consumer (DTC) companies.1</li>
<li>High Margins with Minimal Costs: We will offer a subscription at $49.95 annually. Since no new sequencing is required, the cost of goods sold is minimal (primarily the cost of IT) and the margins should be substantial. Over the next few years, with minimal market penetration we would therefore expect significant revenues, gross profit and longer-term cash flow. &nbsp;</li>
</ul>

Biotech

News

General

ProPhase Labs Launches DNA Complete, To Enrich Existing DNA Ancestry Data With Comprehensive Health Insights

<h2 class="wp-block-heading">New On The Block</h2>
Ari Emanuel&#8216;s sports and entertainment conglomerate, Endeavor Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>), is reviewing a potential sale of IMG tennis assets — including the Miami Open and Madrid Open tennis tournaments. Most of IMG&#8217;s other assets were included in a transaction announced on Thursday with TKO Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), the parent company of Ultimate Fighting Championship (UFC) and <a href="https://www.benzinga.com/topic/wwe">World Wrestling Entertainment (WWE)</a>. 
The Frieze Art Fair, a curated event featuring modern and contemporary works, is also for sale. Endeavor acquired a majority stake in April 2016. The Raine Group is advising Endeavor.
See Also: <a href="https://www.benzinga.com/government/24/10/41549838/uk-launches-antitrust-review-of-synopsys-34-billion-ansys-deal-over-growing-concerns">UK Launches Antitrust Review Of Synopsys&#8217; $34 Billion Ansys Deal Over Growing Concerns</a>
<h2 class="wp-block-heading">Off The Block</h2>
TKO, created a year ago from the <a href="https://www.benzinga.com/general/entertainment/23/09/34455843/wwe-and-ufc-merge-on-tuesday-heres-what-you-need-to-know">merger of the WWE and UFC</a>, acquired sports marketing agency IMG from Endeavor in a $3.25 billion all-equity deal that included Fort Worth, Texas-based Professional Bull Riders and live events business On Location. The sale is expected to close in the first half of 2025. Endeavor will end up owning approximately 59% of TKO. Separately, TKO's board has authorized a share-repurchase program of up to $2 billion of Class A common stock.
PPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) agreed to sell its architectural coatings business in the U.S. and Canada for $550 million to private equity firm American Industrial Partners. This ends a sale process first announced in February. The transaction is expected to close in late 2024 or early 2025. Goldman Sachs &amp; Co. LLC advised PPG on the sale while law firm Hogan Lovells U.S. handled legal matters.
Jif peanut butter maker J.M. Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) jettisoned its cookie brand, Voortman, to snacks company Second Name Brands for $305 million. Reuters first reported about the auction in July. J.M. Smucker also owns Folgers coffee, Hostess baked snacks, and a variety of pet foods, such as Meow Mix and Kibbles &#8216;n Bits.
<h2 class="wp-block-heading">Updates From The Block</h2>
Biotech firm ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) <a href="https://www.nasdaq.com/press-release/prophase-labs-announces-positive-updates-strategic-initiatives-company-anticipates">engaged</a> ThinkEquity to advise the sale of PMI. So far, more than 70 potential acquirers are in consideration. The deal is expected to close in 2025.
Durham, North Carolina-based Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) <a href="https://www.ft.com/content/b31d96e7-9c1c-44d9-b358-ebe8ce7842c1">put</a> plans for a German semiconductor plant on hold. The development comes about two months after activist investment firm, Jana Partners, started urging the Wolfspeed board to explore a sale of the entire company.
Verizon Communications Inc. ((NYSE, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NASDAQ">VZ</a>) offered to buy Frontier Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>) for $38.50 per share. The Frontier board had been considering a sale; it recommended stockholders vote "for" the transaction.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Radford Motors, a luxury car manufacturer owned by British TV personality Ant Anstead, <a href="https://people.com/ant-anstead-supercar-company-radford-motors-files-for-bankruptcy-8733015">filed</a> Chapter 11. People Magazine broke the story. This year, Hiphi, a Chinese EV startup, backed by Human Horizons, filed for bankruptcy in August. E.Go, a German electric car maker, filed for insolvency for the second time in March and entered liquidation in May.
Now Read:
<ul>
<li><a href="EXCLUSIVE: Anthony Scaramucci Predicts 'Acceptance Of Stablecoins' As Digital Dollars With Upcoming Crypto-Friendly Congress">EXCLUSIVE: Anthony Scaramucci Predicts &#8216;Acceptance Of Stablecoins&#8217; As Digital Dollars With Upcoming Crypto-Friendly Congress</a></li>
</ul>

Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt

ProPhase Labs Announces Updates On Strategic Initiatives, Projects Pharmaloz Manufacturing 2025 Revenue Of $16-17M And Pre-Tax Earnings Of $6-7M, Targets PMI Sale In Early 2025 Valued Over $40M, And Engages In Strategic Partnership Talks For BE-Smart Esophageal Cancer Test With Potential Upfront Payment Of $30-50M

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.12) by 175 percent. This is a 1550 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $2.474 million which missed the analyst consensus estimate of $11.175 million by 77.86 percent. This is a 81.28 percent decrease over sales of $13.217 million the same period last year.

Earnings

Earnings Misses

ProPhase Labs Q2 2024 GAAP EPS $(0.33) Misses $(0.12) Estimate, Sales $2.474M Miss $11.175M Estimate

PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. &nbsp;
New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation
Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. ("PMI"), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025. The Company believes that the strategic enhancements to PMI's primary production line have generated increased capacity, revenue opportunities, efficiency as well as diversified and increased product offerings. These enhancements, combined with more favorable pricing, have led to a projected increase in PMI's revenues, margins and profitability going forward. Therefore, ProPhase believes there are several strategic options for PMI in 2024 and 2025 that may provide significant liquidity and value creation for the Company, though there can be no assurance that any transaction will occur. The Company has engaged ThinkEquity as an advisor to pursue strategic alternatives for PMI.
Based on these improvements and the expectation of continued increasing customer demand, the Company believes that beginning in the current Q3 2024, PMI's 12-month forward looking revenue run rate with one production line will be approximately $14-16 million and approximately $5 million in pre-tax net profits. These results are anticipated solely through operation of PMI's first enhanced manufacturing line. To place this in perspective, PMI generated approximately $9.3 million in revenues and reported net losses from operations in calendar year 2023.

Guidance

ProPhase Labs Announces Update On Pharmaloz Manufacturing Progress; Says PMI's 12-Month Forward Looking Revenue Run Rate With One Production Line Will Be ~$14M-16M And ~$5M In Pre-Tax Net Profits

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.18) by 61.11 percent. The company reported quarterly sales of $3.634 million which missed the analyst consensus estimate of $9.860 million by 63.14 percent. This is a 81.17 percent decrease over sales of $19.303 million the same period last year.

Earnings Beats

ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate

Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. &nbsp;
Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual's entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company's BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.
Antibody drug conjugates (ADCs) are specialized treatments that differ from traditional chemotherapy by specifically targeting cancer cells. ADCs use a linker to attach chemotherapy agents to a monoclonal antibody, which then binds to a unique marker found on the surface of cancer cells. This targeted approach helps to minimize damage to healthy cells and other side effects. ADCs represent a potent class of cancer therapies, blending the specificity of monoclonal antibodies with cytotoxic drugs. Leveraging ZenQ-AI with both genomic and proteomic data is believed to enable the rapid identification of biomarkers and mutations driving cancer, streamlining the design of ADCs for precise targeting. This integration promises more effective and personalized treatments, though rigorous experimental validation remains crucial for ensuring safety and efficacy of new therapeutic candidates.
"The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we've curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs. "This unique combination of sophisticated AI and rich, diverse genomic and proteomic data sources enhances our approach to cancer treatment as both innovative and effective."

ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development

ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. &nbsp;
Ted Karkus, CEO of ProPhase Labs, commented, "The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection. Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future. This groundbreaking diagnostic test is a patent-protected method for identifying esophageal cancer markers and a key component of ProPhase Labs' mission to enhance early detection and facilitate personalized treatment strategies and reflects our commitment to saving lives and improving patient care."
The BE-Smart test constitutes a major innovation in the detection and management of esophageal adenocarcinoma ("EAC") and stands at the forefront of a diagnostic revolution. ProPhase intends to pursue and seeks to capture a significant share of a multi-billion-dollar market for EAC diagnostics. The Company anticipates reimbursement rates ranging between $1,000 and $2,000 per test based on CPT codes (as defined below) of similarly complex tests[1]. By addressing the annual estimated demand for 7 million endoscopies in the U.S. alone for severe GERD and Barrett's Esophagus cases, the BE-Smart test targets an initial market size of $7 billion to $14 billion.
ProPhase Labs, in collaboration with mProbe Inc., a precision health and medicine company utilizing clinical proteomics in the oncology space, is nearing completion of rigorous validation studies of the BE-Smart test, which at its core aims to accurately implement our patent-protected method for identifying esophageal cancer markers. This phase of analytical validation is being completed in parallel with clinical verification by institutions including the Mayo Clinic and Genesis Clinical, a leader in statistical analysis and algorithm development.
"Once completed, we anticipate that the analytical validation studies will demonstrate to the scientific and medical community the BE-Smart test's reliability, accuracy, and readiness for widespread clinical use," said Igor Ban, PhD, director of Research and Development at ProPhase. "Understanding the critical role of extensive data in improving diagnostic tools, we are reaching out to research hospitals across the US and Europe to form partnerships. These collaborations will provide BE-Smart with access to a wider array of esophageal tissue samples, including those from diverse patient demographics and various stages of Barrett's Esophagus and EAC. Following commercialization, this invaluable data pool will enable BE-Smart to conduct more nuanced analyses, continuously advancing the test's sensitivity, specificity, and overall utility."
Within the coming months, the Company anticipates submitting the documentation required for BE-Smart's Advanced Diagnostic Laboratory Test (ADLT) application, a subclass of the Current Procedural Terminology ("CPT") Proprietary Laboratory Analyses ("PLA") coding system. ProPhase plans to commercially launch BE-Smart following CPT code approval, which is anticipated in the second half of 2024, paving the way for a new era in cancer diagnostics.
Obtaining CPT codes is important for billing purposes, enabling ProPhase Labs to bill for providing the test services and receive reimbursement from insurance companies. The Company is diligently preparing and compiling all necessary documentation to ensure compliance with regulatory standards.
Developed over six years, the BE-Smart test leverages sophisticated proteomics to improve early detection of EAC, a valuable tool given that EAC is among the deadliest cancers with no effective currently available targeted treatments. This unfortunate situation, where approximately 80-90% of EAC patients face a fatal outcome, highlights the important need for a groundbreaking diagnostic tool like BE-Smart.
Through its partnership with Genesis Clinical, the Company is bolstering BE-Smart's capability to stratify esophageal cancer risk accurately, a development of immense value to patients and insurance providers. The test's innovative approach not only promises early detection but also promises to stratify patients into low or high-risk groups with remarkable accuracy.
Mr. Karkus continued, "This risk assessment is crucial, offering peace of mind to those at low risk and potentially sparing them from unnecessary and costly annual endoscopies. For high-risk individuals, it facilitates timely interventions, such as ablation procedures reimbursed by insurance, offering a lifesaving and cost-effective solution compared to the management of advanced disease. Being able to provide targeted patient care strategies, we believe that the BE-Smart test stands at the forefront of transforming patient management in EAC, embodying a holistic approach to enhancing patient outcomes through state-of-the-art early detection and personalized care plans. And the beauty of the test is that it is performed on slivers of tissue specimens that are already being extracted during routine endoscopy procedures."

ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.26) by 96.15 percent. This is a 537.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $10.69 million by 59.30 percent. This is a 80.06 percent decrease over sales of $21.82 million the same period last year.

ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million.
&bull; NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $182.13 million.
&bull; Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $1.61 billion.
&bull; Hibbett (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) is projected to report quarterly earnings at $2.55 per share on revenue of $477.49 million.
&bull; RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $66.52 million.
&bull; KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.32 million.
&bull; Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is estimated to report earnings for its fourth quarter.
&bull; Desktop Metal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DM#NYSE">DM</a>) is projected to report quarterly loss at $0.05 per share on revenue of $50.83 million.
&bull; Paltalk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALT#NASDAQ">PALT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $3.53 million.
&bull; GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) is likely to report quarterly earnings at $0.58 per share on revenue of $224.15 million.
&bull; Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is estimated to report quarterly earnings at $1.66 per share on revenue of $6.89 billion.
&bull; Buckle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) is expected to report quarterly earnings at $1.44 per share on revenue of $383.63 million.
&bull; Summit Midstream Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMLP#NYSE">SMLP</a>) is projected to report earnings for its fourth quarter.
&bull; CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $58.86 million.
&bull; ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is likely to report quarterly loss at $0.26 per share on revenue of $10.69 million.
&bull; Tredegar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>) is estimated to report earnings for its fourth quarter.
&bull; Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) is expected to report quarterly loss at $0.07 per share on revenue of $304.52 million.
&bull; Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is likely to report quarterly loss at $0.12 per share on revenue of $32.06 million.
&bull; Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) is likely to report quarterly earnings at $0.11 per share on revenue of $136.70 million.
&bull; Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $111.85 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Consumer Pf Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSS#NASDAQ">CPSS</a>) is estimated to report earnings for its fourth quarter.
&bull; Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is projected to report quarterly earnings at $0.71 per share on revenue of $60.65 million.
&bull; High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $94.67 million.
&bull; Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $32.65 million.
&bull; Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) is likely to report quarterly loss at $1.19 per share on revenue of $11.52 million.
&bull; AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $66.80 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALTI

BFRI

CBAT

CPSS

GRPN

HIBB

HITI

KVHI

LEGH

OXSQ

PALT

SHCO

SMLP

Earnings Scheduled For March 15, 2024

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is set to give its latest quarterly earnings report on Friday, 2024-03-15. Here's what investors need to know before the announcement.
Analysts estimate that ProPhase Labs will report an earnings per share (EPS) of $-0.26. 
ProPhase Labs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.11, which was followed by a 10.78% drop in the share price the next day.
Here's a look at ProPhase Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.19</td>
<td>-0.14</td>
<td>-0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.30</td>
<td>-0.20</td>
<td>0.03</td>
<td>-0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-2.0%</td>
<td>-7.000000000000001%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710428437_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ProPhase Labs were trading at $5.05 as of March 13. Over the last 52-week period, shares are down 35.96%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRPH/earnings">To track all earnings releases for ProPhase Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ProPhase Labs's Earnings: A Preview

HC Wainwright &amp; Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) with a Buy and maintains $11 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $11 Price Target

ProPhase&nbsp;Labs, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>),&nbsp;a&nbsp;next generation biotech, genomics and diagnostics&nbsp;company, today announced important developments in the Company&#39;s efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test. 
&nbsp;
BE-Smart is a novel diagnostic test that is intended to detect and quantify early signs of certain types of cancer in individuals with Barrett&#39;s esophagus, a condition known to significantly increase the risk of developing esophageal cancer. This breakthrough test, in development for nearly five years, is nearing completion of clinical studies. If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024. Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test&#39;s precision and reliability in identifying esophageal adenocarcinoma risk. These additional specimens continue to achieve consistently positive preliminary results. All tested samples are currently under review by Genesis Biotechnology Group (&quot;Genesis&quot;), a leading independent statistical analysis firm, for independent verification of the results.
Key Milestones and Innovations:
-BE-Smart is the only mass spectrometry-based diagnostic intended for cancer progression surveillance in Barrett&#39;s esophagus patients. The test is believed to have both high diagnostic (disease type and stages confirmation) and prognostic (molecular analysis of tissue indicative of disease progression or stability) capabilities. Subject to successfully completing the testing phase and regulatory compliance, both aspects of the test will be bundled into one offering for use by gastroenterologists, and GI pathologists and other health care professionals. The ability to identify whether an individual is at high-risk would offer a transformative approach in diagnosing and managing this deadly disease, potentially saving lives and reducing healthcare costs.
- The United States Patent and Trademark Office (USPTO) has granted ProPhase Labs a patent safeguarding the BE-Smart technology and extending protection to similar biomarker discovery processes for various diseases.
- The test has demonstrated molecular precision in excess of&nbsp;99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.
- Recent studies on additional samples using a brush technique appear to confirm the test&#39;s versatility and effectiveness compared to traditional biopsy methods.
-As a laboratory-developed test (&quot;LDT&quot;), BE-Smart will continue to develop and adapt to new potential protein markers that may arise after the completion of the RNA-Seq data analysis currently being conducted at the Mayo Clinic.
Future Directions and Impact:
As an LDT, BE-Smart&#39;s flexibility allows for the incorporation of emerging protein markers, enhancing its diagnostic power. ProPhase anticipates the completion of Genesis Biotechnology Group&#39;s analysis by early&nbsp;Q2, followed by subsequent strategic collaborations to then secure reimbursement rates and enable wide-scale adoption of the test. BE-Smart uses high throughput mass spectrometer technology that we believe will enhance national deployment, targeting over 20 million Americans monitored for Barrett&#39;s esophagus.
&quot;A recent Wall Street Journal op-ed from February 2, 2024 spoke about early cancer detection and improving survival rates, but BE-SMART does one better, it detects hallmarks of carcinogenesis before it even develops, allowing for a simple procedure to remove the potentially dangerous cells, a true game changer for gastroenterology, &quot;said Ted Karkus, CEO of ProPhase Labs. &quot;We believe that BE-Smart potentially solves many of the problems that plague other tests in the field, our test doesn&#39;t need multiple samples and the test isn&#39;t limited by staining and subjective diagnosis. BE-Smart requires only a small amount of tissue for testing and allows for extremely high throughput. Once commercialized, our goal is for this to be the standard of care test used on the over 20 million people being monitored by gastroenterologists for Barrett&#39;s esophagus. If we are able to attain reimbursement rates of just&nbsp;$1,000&nbsp;-&nbsp;$2,000, which cannot be assured, the initial addressable US market alone represents an enormous market for us.&quot; Mr.&nbsp;Karkus&nbsp;concluded.&nbsp;
About the BE-Smart Test
The BE-Smart Esophageal Pre-Cancer Diagnostic Screening test is aimed at early detection of esophageal cancer. It has already been tested by an independent test lab, mProbe, Inc. on over 200 human samples and has shown an area under curve of greater than&nbsp;99%1&nbsp;in distinguishing highly impactful histologic classifications. ProPhase Labs plans to pursue initial commercialization of the BE-Smart test as an LDT. The goal of widespread adoption of the BE-Smart diagnostic test would allow health care providers to initiate potentially lifesaving early treatment processes such as an ablation procedure to remove the precancerous cells and could also significantly reduce unnecessary endoscopies.

ProPhase Labs Announces Progress In BE-Smart Esophageal Cancer Test Development USPTO Grants Additional Broad Patents For BE-SMART

ProPhase Labs Announces Preliminary Results For Dietary Supplement Equivir, Co. Says Prelim Results Indicate It 'has the potential to support and maintain immunity'

Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and Profitability Company in Late-Stage Discussions with Two Additional Large Global Brands Which, if Consummated, Could more than Triple Run-Rate of Revenues Before Year-End 2024
Garden City, NY, Jan. 23, 2024 (GLOBE NEWSWIRE) -- ProPhase&nbsp;Labs, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"),&nbsp;a&nbsp;next generation biotech, genomics, therapeutics and diagnostics&nbsp;company, today&nbsp;announces significant progress at Pharmaloz Manufacturing, Inc. (PMI), its wholly owned subsidiary.
With the implementation of recent price increases across its entire product line, PMI has transitioned to significant projected 2024 profitability starting with Q1 2024. In view of favorable current market conditions and demand for PMI's services and products, PMI is optimistic that it will experience continued favorable pricing for the near to intermediate term.
PMI's operational enhancements have helped drive its current success. PMI recently acquired cutting-edge automation equipment and, with other operating efficiencies, is set to escalate plant capacity by over 50%, raising annual production capability from below $10 million to over $15 million.
In addition to the price increases, increased capacity and transition to profitability, PMI has signed deals with two top-tier lozenge brands. These new arrangements are projected to inject an additional $5 million in annual revenue and more than $1.25 million in additional yearly pre-tax net profits. One of these brands is also poised to leverage PMI's comprehensive blister packing capabilities, further diversifying its manufacturing portfolio.
In addition to the contract awards announced above, PMI has been working on bench samples for the past year for two major global brands. These brands represent two of the largest names in the global lozenge market.
PMI is not stopping there. The installation of a second lozenge production line and further automation in Q2 2024 are projected to approximately double capacity to a $30-$35 million potential run-rate. Additional equipment set to arrive by Q4 2024 could increase annual production capabilities to a range of $60-$80 million, based on a 3 ½ day workweek. This production capacity could be further increased, if demand warrants it, with additional staffing to extend the workweek.
Ted Karkus, CEO of ProPhase Labs, reflects on this transformative journey: "What began as a modest manufacturing unit solely dedicated to our Cold-EEZE&#xAE; contract manufacturing has evolved into a top-tier facility producing premium lozenges for global brands. Our roadmap envisages scaling this business in the next 18-24 months from under $10 million in annual revenue to a potential $80-$100 million production capacity with healthy net profit margins. With prospective global partnerships, we're collaborating with a leading engineering and consulting firm to potentially enhance production capacity to $100-$200 million in annual revenues by the end of 2025. Of course, there can be no assurance that we will in fact be able to win new business at these levels, or that such new business will deliver the projected gross margins, but that is the goal."
"The projected increased profitability at PMI will help offset some of the investment and expenses related to the development of our Nebula Genomics business and build out of our world-class whole genome sequencing lab in Garden City, NY, as well as preparation for the commercialization of our BE-Smart Esophageal Cancer test," Mr. Karkus concluded.

Contracts

ProPhase Labs Announces Progress At Pharmaloz Manufacturing Accelerating Expansion, Improves Pricing, Boosts Profitability And Secures New Contracts

Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024 Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth
Garden City, NY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase&nbsp;Labs, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"),&nbsp;a&nbsp;next generation biotech, genomics, therapeutics and diagnostics&nbsp;company, today&nbsp;reported that Jed Latkin, a long-time operations and finance expert, has accepted the role as COO of the parent company.
Mr. Latkin, a Columbia MBA, represented the seller in&nbsp;the Company's acquisition of the BE-SMART Esophageal Cancer Test. He immediately became a consultant to ProPhase to help develop its biotech assets including the BE-Smart test as the Company works toward its commercialization, as well as work on the Company's other subsidiaries.
Mr. Latkin has been&nbsp;in the finance and management industry since 1996 and has worked with over 15 pharmaceutical companies over the last ten years alone. He has served as CEO, CFO or COO of multiple companies in Biotech, manufacturing, and other verticals.&nbsp;
Mr. Latkin has also served as a board member of several key industry groups that has allowed him to build a diverse network of contacts that will help&nbsp;ProPhase&nbsp;find key partnerships over the next several years. In his role at&nbsp;ProPhase&nbsp;he will not only serve as COO of the Company but also as the head of the newly restructured finance department.
"ProPhase&nbsp;has successfully transformed itself once again from a company that was mainly focused on the covid testing lab business, into a diversified manufacturing, biotech and genomics powerhouse that has multi-billion-dollar potential," said Ted&nbsp;Karkus, CEO of&nbsp;ProPhase&nbsp;Labs.
"We anticipate an acceleration in growth at both Nebula Genomics and Pharmaloz Manufacturing, as well as commercialization of our BE-SMART esophageal cancer test, during 2024. Our entire senior team at ProPhase has worked very closely with Jed over the past year and our Board of Directors has spent meaningful time with him as well. Given our multiple high growth prospects in 2024, we felt that it was the perfect time to hire him as our COO, to help develop and grow these subsidiaries. With&nbsp;his diversified background at a multitude of companies spanning from biotech to manufacturing, he is an ideal fit for this multi-faceted COO role," Mr.&nbsp;Karkus&nbsp;concluded.&nbsp;

Management

Prophase Poised To Ramp Up Growth At Pharmaloz And Nebula Genomics In 2024; Company Announces The Hiring Of Long-Time Industry Veteran Jed Latkin As COO To Help Build And Manage This Growth

HC Wainwright &amp; Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) with a Buy and lowers the price target from $14 to $11.

HC Wainwright & Co. Maintains Buy on ProPhase Labs, Lowers Price Target to $11

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.20) by 50 percent. This is a 600 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $8.37 million which missed the analyst consensus estimate of $13.06 million by 35.95 percent. This is a 65.43 percent decrease over sales of $24.20 million the same period last year.

ProPhase Labs Q3 EPS $(0.30) Misses $(0.20) Estimate, Sales $8.37M Miss $13.06M Estimate

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here's what investors need to know before the announcement.
Analysts estimate that ProPhase Labs will report an earnings per share (EPS) of $-0.19. 
ProPhase Labs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.06, which was followed by a 2.23% drop in the share price the next day.
Here's a look at ProPhase Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.09</td>
<td>0.02</td>
<td>0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.20</td>
<td>0.03</td>
<td>-0.08</td>
<td>0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.23%</td>
<td>-6.71%</td>
<td>-6.51%</td>
<td>7.02%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699462886_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ProPhase Labs were trading at $4.59 as of November 07. Over the last 52-week period, shares are down 59.86%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRPH/earnings">To track all earnings releases for ProPhase Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ProPhase Labs Earnings Preview

Prophase Labs Inc Says Pharmaloz Plan Is To Build Capacity With A Goal To Attain A Revenue Run-rate Of $60 To $80M By Year-End 2024; Pharmaloz Is Projected To Achieve A Run-Rate Of $15M In Annualized Revenues & Run-Rate Of $3M+ In Gross Profit During Q1

Rare Stock Picks In May 2024 - From 29 Discerning Analysts

ProPhase Labs updates on Pharmaloz Manufacturing's impact on results

ProPhase Labs Q2 2024 Earnings Preview

Here's the major earnings before the open tomorrow

ProPhase Labs misses Q2 estimates

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ProPhase Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/prph-stock-quote/">PRPH</a>) just reported results for the second quarter of 2024.<ul><li>ProPhase Labs reported earnings per share of -33 cents. This was below the analyst estimate for EPS of -24 cents.</li><li>The company reported revenue of $2.47 million.</li><li>This was 77.85% worse than the analyst estimate for revenue of $11.17 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/prph-stock-earnings-prophase-labs-for-q2-of-2024/">PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q2 2024

ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript

ProPhase Labs, Inc. 2024 Q2 - Results - Earnings Call Presentation

The latest update is out from Prophase Labs ( ($PRPH) ). ProPhase Labs, Inc. has fallen out of compliance with Nasdaq's audit committee requirement...

ProPhase Labs Seeks Director Amidst Nasdaq Compliance Issue

ProPhase Labs (PRPH) announced the launch of DNA Complete, offering a direct-to-consumer DNA test that sequences virtually 100% of a customer's gen...

ProPhase Labs launches DNA Complete, a direct-to-consumer DNA test

AMVMF

ARCO

ASAI

ASND

BCLI

BKKT

BLUE

CEIX

CELH

CRMD

DOLE

EOLS

EONGY

ESLT

FENY

FLNG

FOXF

FTNT

GLBE

HLMN

HNHAF

IMNN

IPWR

ITRM

KARO

KMDA

KOMP

KPLT

MDWD

MEDIF

MGIC

MSOS

NFLX

ONDS

ORCL

OTLK

PFGC

POAI

RSKD

SACH

SUNS

TCEHY

TROW

TSAT

VISL

VWDRY

WKHS

Press Releases

ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress

PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14

ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024

ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025

ProPhase Labs to Present at the 2024 ThinkEquity Conference

Health Care

ProPhase Labs Launches DNA Complete®: Transforming Direct-to-Consumer Genetic Testing for Health, Wellness, and Enhanced Ancestry

Comments

ProPhase Labs

매도 수량

ProPhase Labs (NASDAQ:PRPH) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌